Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.46 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428711 | 0.91 | GRM2 (0.51) | HPGDERN1PLAURGRM2ALDH1A1 | |
| SCHEMBL31429121 | 0.90 | AR (0.56) | MAPTMEN1KMT2AHPGDERN1 | |
| SCHEMBL31428712 | 0.89 | GRM2 (0.49) | HPGDERN1GRM2ARALDH1A1 | |
| SCHEMBL31428481 | 0.87 | ERN1 (0.52) | MEN1KMT2AHPGDERN1PLAUR | |
| SCHEMBL31428671 | 0.86 | HPGD (0.50) | HPGDERN1PLAURGRM2ALDH1A1 | |
| SCHEMBL31429056 | 0.86 | MAPT (0.54) | MAPTMEN1KMT2AHPGDPLAUR | |
| SCHEMBL31428987 | 0.86 | RIPK1 (0.44) | HPGDERN1GRM2ALDH1A1RIPK1 | |
| SCHEMBL24977240 | 0.85 | HPGD (0.45) | MAPTMEN1KMT2AHPGDERN1 | |
| SCHEMBL31428554 | 0.85 | HPGD (0.44) | MAPTHPGDERN1PLAURALDH1A1 | |
| SCHEMBL31428876 | 0.84 | MKNK1 (0.53) | HPGDERN1GRM2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | MAPT 4513/4885MEN1 1712/4885KMT2A 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.